Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multinational, Multicenter, Observer-Blinded, Randomized, Active-Controlled Trial to Evaluate the Immunogenicity and Safety of the Preventive COVID-19 Vaccine AdCLD-CoV19-1 OMI Administered As a Booster to Adults Aged 19 Years Old and Above

NCT05993325 is registered in ClinicalTrials.gov with Cellid Co., Ltd. as lead sponsor.

NCT NCT05993325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05993325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multinational, Multicenter, Observer-Blinded, Randomized, Active-Controlled Trial to Evaluate the Immunogenicity and Safety of the Preventive COVID-19 Vaccine AdCLD-CoV19-1 OMI Administered As a Booster to Adults Aged 19 Years Old and Above
Lead sponsor
Cellid Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 27, 2023
Completion date
November 30, 2025
Enrollment
4,000 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, vaccines